Once-daily beta-blocker OK'd for three indications

Carvedilol extended-release capsules (Coreg CR, GlaxoSmithKline), a new once-daily third-generation beta-blocker, has received FDA approval for three indications. The capsule utilizes Flamel Technologies' proprietary Micropump technology, which controls the release of drug from the capsule over 24 hours. Coreg CR can be used to treat hypertension, post-myocardial infarction left ventricular dysfunction, and mild to severe heart failure. According to Glaxo, shipments will begin in the first quarter of 2007.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, .